Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “PHARMACEUTICALS”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,207 records · Page 67

Carbon fixation systems in plants and algae

Provided are heterologous nucleic acid constructs, vectors and methods for elevating cyclic electron transfer activity, improving carbon concentration, and enhancing carbon fixation in C3 and C4 plants, and algae, and producing biomass or other products from C3 or C4 plants, and algae, selected from among, for example, starches, oils, fatty acids, lipids, cellulose or other carbohydrates, alcohols, sugars, nutraceuticals, pharmaceuticals, fragrance and flavoring compounds, and organic acids, as well as transgenic plants produced thereby. These methods and transgenic plants and algae encompass the expression, or overexpression, of various combinations of genes that improve carbon concentrating systems in plants and algae, such as bicarbonate transport proteins, carbonic anhydrase, light driven proton pump, cyclic electron flow regulators, etc.

Sayre, Richard Thomas↗

Small molecule inhibitors for treatment of alpha viruses

An in vitro assay was designed to measure the activity of the alphavirus non-structural protein 2 (nsP2), which is the viral protease and is required for viral replication. By taking advantage of fluorescence-resonance energy transfer between two proteins, a protease cleavage assay was generated. This was utilized for high-throughput screening of 40,000 small molecules. Inhibitors were validated using cell-based assays to measure alphavirus infection and cytotoxicity. Certain compounds were then characterized for anti-viral efficacy in various cell lines in numerous assays. Compounds were tested against Chikungunya virus, Venezuelan Equine Encephalitis virus, Rift Valley Fever virus, and Zika virus. Three compounds (compounds I, II, and III) showed pan-alphavirus anti-viral efficacy at concentrations that did not result in cell toxicity. An additional compound, structure IV, showed broad spectrum inhibition of all viruses tested. Pharmaceutical preparations and methods of treatment including these compounds are provided herein.

60 APPLIED LIFE SCIENCES↗

Butyric Acid Production from Delignified Corn Stover Using Thermophilic Bacterial Co-Cultures

Butyric acid (BA) is a valuable platform chemical in the food and pharmaceutical industries, and it is also a potential precursor for the production of biobutanol and sustainable aviation fuels (SAFs). BA is mainly synthesized from petroleum; thus, cost-effective, and sustainable alternatives for its production are attracting the interest of several sectors. The present work proposes a solids-to-acids bioprocess to produce BA from corn stover utilizing a co-culture that consists of two thermophilic bacteria, Clostridium thermocellum, a well-known efficient degrader of insoluble and oligomeric cellulosic substrates, and Clostridium thermobutyricum, a highly efficient BA producer from monomeric sugars. After initial proof of concept experiments, a series of optimization studies were carried out to evaluate the process limits of this co-culture. First, the co-cultivation of both microorganisms at different inoculum sizes in deacetylated and mechanically refined corn stover (DMR) was evaluated. No significant differences were found on the solids deconstruction and carbohydrates utilization among all the treatments. In addition, BA production was similar under all conditions, ranging between 2.1 and 2.4 g/L. Next, the deconstruction, and BA production capabilities of the co-culture at increased DMR solids contents (3, 4.5, and 6% (w/v)) were tested. Although no difference was observed in the solids deconstruction and carbohydrates utilization among treatments, BA production increased concomitantly to solids loading; the maximum values observed were 2.8, 3.6, and 6.2 g/L in the 3, 4.5, and 6% treatments, respectively. In fact, BA production did not reach its absolute maximum in the 6% treatment after 160 h of fermentation. Lastly, a fed-batch experiment was performed to investigate the co-culture capabilities and possible system constraints to achieve higher BA titers. Data on substrate modifications and product formation as well as on the growth of each microorganism will be shown. Results from this work demonstrate a promising bioprocess approach for the production of BA from lignocellulosic biomass using a thermophilic bacterial co-culture.

bacteria↗

The Importance of Chemical Research to the U.S. Economy

Chemistry plays a pivotal role in the strength of the U.S. economy and the advancement of humankind. Chemists' achievements include life-saving pharmaceuticals, advanced energy solutions, improved agricultural productivity, and novel materials used in products from clothing to electronic devices. The many sectors reliant on the U.S. chemical economy account for about 25% of the U.S. GDP and support 4.1 million U.S. jobs. However, a new and evolving chemistry landscape requires changes with regard to funding, training, and a focus on integrating sustainability into manufacturing, product usage, and product disposal. This report identifies strategies and options for research investments that will support U.S. leadership while considering environmental sustainability and developing a diverse chemical economy workforce with equitable opportunities for all chemistry talent. The report recommends that funding agencies and philanthropic organizations who support the chemical sciences fund as large a breadth of fundamental research projects as possible. Chemical industry and their partners at universities, scientific research institutions, and national laboratories should align the objectives of fundamental research to directly assist with new practices toward environmental stewardship, sustainability, and clean energy. Additionally, the report recommends that funding agencies make substantial investment toward education research to enable innovative ways of teaching about emerging concepts, tools and technologies.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Metal complexes and methods of making the same

Disclosed herein are embodiments of metal complexes and methods of making the same. The disclosed method embodiments provide a one-step approach to making metal complexes, such as complexes comprising lanthanide metals, rare earth metals, transition metals, main group metals, and/or actinide metals that can be used various applications, such as in separations technology, catalysis (e.g., catalysts for pharmaceutical synthesis and/or catalysts for biomass conversion), nuclear chemistry, LED phosphors, scintillator materials, magnetic materials, and nuclear fuels.

Kiplinger, Jaqueline↗

High molecular weight polysaccharide that binds and inhibits virus

This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Konowalchuk, Thomas W.↗

Assessment of Quality Assurance Measures for Radioactive Material Transport Packages not Requiring Competent Authority Design Approval - 13282

The majority of transports of radioactive materials are carried out in packages which don't need a package design approval by a competent authority. Low-active radioactive materials are transported in such packages e.g. in the medical and pharmaceutical industry and in the nuclear industry as well. Decommissioning of NPP's leads to a strong demand for packages to transport low and middle active radioactive waste. According to IAEA regulations the 'non-competent authority approved package types' are the Excepted Packages and the Industrial Packages of Type IP-1, IP-2 and IP-3 and packages of Type A. For these types of packages an assessment by the competent authority is required for the quality assurance measures for the design, manufacture, testing, documentation, use, maintenance and inspection (IAEA SSR 6, Chap. 306). In general a compliance audit of the manufacturer of the packaging is required during this assessment procedure. Their regulatory level in the IAEA regulations is not comparable with the 'regulatory density' for packages requiring competent authority package design approval. Practices in different countries lead to different approaches within the assessment of the quality assurance measures in the management system as well as in the quality assurance program of a special package design. To use the package or packaging in a safe manner and in compliance with the regulations a management system for each phase of the life of the package or packaging is necessary. The relevant IAEA-SSR6 chap. 801 requires documentary verification by the consignor concerning package compliance with the requirements. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Current Status of Human Resource Training Program for Fostering RIBiomics Professionals

RI-Biomics is a state-of-the-art radiation fusion technology for evaluating in-vivo dynamics such as absorption, distribution, metabolism and excretion (ADME) of new drug candidates and biomaterials using radioisotope (RI), and quantitative evaluation of their efficacy via molecular imaging techniques and animal models. The RI-Biomics center is the sole comprehensive research and experiment complex in Korea that can simultaneously perform the radio-synthesis of drug candidate with radioisotope, analysis, and molecular imaging evaluation with animal model. Molecular imaging techniques, including nuclear imaging (SPECT and PET), near-infrared fluorescent (NIRF) imaging, and magnetic resonance imaging (MRI), are the cutting-edge technologies for evaluating drug candidates. Since they allow in vivo real-time imaging of the diseased site, monitoring the biodistribution of drug and determining the optimal therapeutic efficacy following treatments, we have integrated RI-ADME and molecular imaging to provide useful information for drug evaluation and to accelerate the development of new drugs and biomaterials. The RI-Biomics center was established with total investment of 18 million $ during four years from 2009 to 2012 in order to develop a comprehensive analyzing system using RI for new drug development as an axis for national growth in the next generation. The RI-Biomics center has labeling synthesis facility for the radiosynthesis of drug candidate with radioisotope such as Tc-99m, I-125, I-131, F-18, H-3 and C-14 using hot cell. It also includes RI-general analysis facilities, such as Radio-HPLC, LC/MS, GC/MS, gamma counter that can analyzing the radio-synthesized materials, and animal image analysis facilities that developed small animal imaging equipment such as SPECT/PET/CT, 7 T MRI, in-vivo optical imaging system and others. In order to achieve the system to verify safety and effectiveness of the new drugs using RI, it is necessary to establish a human resource training program for fostering RI-Biomics professionals in the following key fields; (1) Radio-pharmaceuticals synthesis and labeled compound development, (2) Development of RI-ADME in the living object and image assessment technology. Personnel training program that carries out theoretical education and practical training in the field related to RI-Biomics in parallel is being conducted. Internship training for university students has been administered twice already while educational program for the existing professionals in the RI-Biomics field will be carried out during the summer of 2014. The human resource training program for combination of RIADME and different molecular imaging techniques can offer synergistic advantages to facilitate understanding RIADME and fostering RI-ADME professionals. (authors)

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Tritium Recovery From Mixed Waste - 17004

Nuclear Sources and Services (NSSI) in Houston, TX houses a unique infrastructure to recover tritium from a variety of different streams for re-use. NSSI accepts gaseous, aqueous, and tritiated-solid feedstock. For example, titanium-tritide foils from spent neutron generator sources are de-tritiated at 1000 deg. C. Tritium gas is recovered from a variety of metal getter beds. Tritiated liquid that is desorbed from zeolite drier beds or generated while reconditioning nickel beds is transferred to a Combined Electrolysis Catalytic Exchange (CECE) system to concentrate the tritium fraction before the gas is transferred to a hydrogen isotope separator for enrichment. Mixed-waste liquids, typically generated in the pharmaceutical industry, are converted to tritiated water and inactive gaseous effluents using a high-temperature, two-stage, catalytic-oxidation destruction process. The destruction efficiency of solvents is extremely high, typically in the 99.9999% to 99.99999% range. The resultant water containing tritium is also directed to the CECE subsystem. At present, liquid activities ranging from the 0.37 MBq/L (10 μCi/L) to 740 GBq/L (20 Ci/L) can be processed economically. The CECE subsystem has de-tritiated 2 metric tons of heavy water per year and is designed to de-tritiate up to 30 metric tons of light water per year. NSSI is licensed to operate within a 2-gram tritium inventory limit. Recently the Mixed-Waste Oxidation Facility that can process up to 40 liters of liquid per day has been upgraded to reduce the corrosive effects of halogen-based mixed wastes on the effluent scrubbing system. This paper will outline the key features of this system and discuss the effectiveness of the upgrades and the operational parameter space. (authors)

07 ISOTOPE AND RADIATION SOURCES↗

Testing and Starting up of the Plasma Melting Facility for Industrial Treatment of Radioactive Waste - 17362

The operation and maintenance of nuclear power plants, the nuclear fuel cycle in general, research laboratories and pharmaceutical, medical and industrial facilities generate low-level radioactive waste which, along with the historical radioactive waste from past nuclear activities, needs to be treated and stored, awaiting final disposal. Plasma technology offers a very effective way of treating this waste with a high volume reduction factor (VRF), free from organics, liquids and moisture, and meets without a doubt the acceptance criteria for safe storage and disposal. By means of a plasma beam of approximately 5000 deg. C, the inorganic materials are melted into a glassy slag, containing most of the radioactive isotopes while the organic material is gasified and afterwards oxidized in an afterburner and purified in an off-gas cleaning system. This paper describes the principles of plasma, the different waste feed systems, off-gas treatment and operational experience and future plasma plants. More specifically, it presents the new full-scale plasma facility for the treatment of radioactive waste at the Kozloduy Nuclear Power Plant in Bulgaria for which construction and assembly was finalized end of August 2016. It also describes in more detail the Site Acceptance Tests (SAT) of this facility. This facility is designed and built as an EPC contract by the Joint Venture Iberdrola Ingenieria y Construccion (Spain) and Belgoprocess (Belgium). (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Innovative Solutions To Solve Complex Radioactive Waste Management Problems In The U.S. - 2017 Richard S. Hodes, M.D. Honor Lecture Award - 17609

Ever since Wilhelm Roentgen, Henri Becquerel, and Marie Curie discovered x-rays, radioactivity, and radium, respectively, at the turn of the nineteenth century, nuclear technologies have continued to evolve and significantly enrich the quality of life for mankind. The evolution of such technologies has enabled our society to diagnose medical illnesses without the need for invasive surgeries, treat cancers, conduct research, develop new kinds of pharmaceuticals, preserve our food supply, and generate over 20% of our nation's electricity from commercial nuclear power plants. While these life-changing technologies have significantly enriched our quality of life and advanced our understanding of the sciences, they also generate radioactive waste that must be managed responsibly in a manner that protects public health. Over the past several decades, decision makers have developed a patchwork of policies to safely manage radioactive wastes-policies that are not necessarily based on the risk posed to public health, but more often on the origins of the waste and the manner in which they are defined in federal legislation. However, in the past several years, much progress has been made to better risk-inform the practices of managing Low-Level Radioactive Waste (LLW) in the United States. In 2012, the nation's first regional commercial facility for disposing of Class A, B, and C LLW since the U.S. Congress enacted the Low-Level Radioactive Waste Policy Act of 1980, as amended in 1985, was opened in Andrews County, Texas. Since then, other innovative LLW management solutions have emerged, ranging from cost-effective disposal options for wastes with very low levels of radioactivity to depleted uranium, and perhaps ultimately, for waste exceeding the concentration-based limits for Class C LLW (i.e., Greater Than Class C LLW) as specified in Title 10 of the Code of Federal Regulations (CFR), chap. 61.55. Most recently, a license application for a consolidated interim storage facility for Spent Nuclear Fuel (SNF) is currently under review by the U.S. Nuclear Regulatory Commission (NRC). Should the NRC approve the license application, SNF currently located at 12 shutdown and decommissioned nuclear reactors could be placed into interim storage in Texas. Approval of this license application would facilitate the complete decommissioning of nuclear power plants, returning them to green-fields, and allowing the local communities to re-purpose the lands for further economic development. Over the next decade, many of these waste management challenges that once seemed insurmountable may soon be transformed into a reality. As will be discussed at the award lecture, achieving such possibilities clearly aligns with the vision of creating innovative radioactive waste management solutions for our nation that were championed by the late physician and statesman, Dr. Richard S. Hodes. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Tritium Recycling from Depleted Uranium Beds - 18098

Nuclear Sources and Services Inc. (NSSI) in Houston Texas houses a unique infrastructure to recover and recycle tritium from a variety of different waste streams. NSSI is licensed to operate within a 2-gram tritium inventory limit and accepts gaseous, aqueous, and tritiated-solid feedstock as sources for tritium recovery. For example, titanium-tritide foils from spent neutron generator sources are de-tritiated at 1000 deg. C in a high temperature desorption facility. Tritiated water is concentrated in a Combined Electrolysis Catalytic Exchange (CECE) system before the gas is transferred to a hydrogen isotope separator for tritium recovery. Mixed-waste liquids containing tritium and carbon-14 isotopes, typically generated in the pharmaceutical industry, are converted to tritiated water, CaC14O3, and inactive gaseous effluents using a high-temperature, two-stage, catalytic-oxidation destruction process with 99.9999% efficiency. [1-4] Depleted uranium (DU) beds are unloaded of tritium and chemically de-activated with oxygen in the bed unloading station. Recently NSSI has worked with the EPA to receive and unload tritium from a number of legacy DU beds found at a super fund site. The DU beds were un-characterized and ranged from 10 to 30 years in age. The variety and size of the beds meant that measuring the quantity of tritium by calorimetry would be prohibitively expensive. Ground disposal was problematic due to the unknown tritium inventory in the beds and the pyrophoricity of the depleted uranium. NSSI was able to unload the tritium from a representative sample of two DU beds, collect and measure the total activity of the gas destined for recycling and remove the hazardous material codes of the DU by de-activating the bed with oxygen before disposing them as low active waste. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Assessment of Quality Management for Transport Packages Not Requiring Authority Design Approval - 18194

The majority of transports of radioactive materials are carried out in packages which don't need a package design approval of a competent authority. Low active radioactive materials are transported in such kind of packages e.g. in the medical and pharmaceutical industry and in the nuclear industry as well. In Germany the decision to phase out nuclear energy leads to a strong demand for packages to transport low and middle active radioactive waste due to the dismantling and decommissioning of nuclear power plants. According to IAEA regulations the 'non-competent authority approved package types' are the excepted packages and the industrial packages of Type IP-1, IP-2 and IP-3 and of Type A. For the packages of Type IP-2, IP-3 and Type A an assessment by the German competent authority is required for the quality management for the design, manufacture, testing, documentation, use, maintenance and inspection. In general a compliance audit of the manufacturer of the packaging is required during this assessment procedure. Their regulatory level in the IAEA regulations is not comparable with the regulatory density for packages requiring competent authority design approval. The countries apply different approaches within the assessment of the quality assurance measures in the management system as well as in the quality assurance program of a special package design. To use the package or packaging in a safe manner and in compliance with the regulations a management system for each phase of the life of the package or packaging is necessary. In order to help manufactures, which measurements and documents are needed for the assessment procedure, BAM developed a guideline. The guideline BAM-GGR 016 [5] describes the needed quality management for the design, manufacture, testing, documentation, use, maintenance and inspection of a packaging and the package. The poster to be presented will explain the different requirements of the quality assurance measures and give examples. (authors)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Taking in Nuclear Operation of the Plasma Facility for Treatment Industrial Radioactive Waste - 19346

The operation and maintenance of nuclear power plants, the nuclear fuel cycle in general, research laboratories and pharmaceutical, medical and industrial facilities generate low-level radioactive waste which, along with the historical radioactive waste from past nuclear activities, needs to be treated and stored, awaiting final disposal. Plasma technology offers a very effective way of treating this waste with a high volume reduction factor (VRF), free from organics, liquids and moisture, and meets without a doubt the acceptance criteria for safe storage and disposal. By means of a plasma beam of approximately 5000 deg. C, the inorganic materials are melted into a glassy slag, containing most of the radioactive isotopes while the organic material is gasified and afterwards oxidized in an afterburner and purified in an off-gas cleaning system. This paper describes the principles of plasma, the different waste feed systems, off-gas treatment and operational experience and future plasma plants. More specifically, it presents the new full-scale plasma facility for the treatment of radioactive waste at the Kozloduy Nuclear Power Plant in Bulgaria for which construction and assembly was finalized end of August 2016. It also describes in more detail the Site Acceptance Tests (SAT) of this facility. Previous paper describes the construction and testing of the plasma melting facility at the Kozloduy NPP in Bulgaria. Now the paper focus on the nuclear starting up conducted in May 2018 with real radioactive waste and illustrates the first operational results such as types of waste treated, volume reduction factors, etc The Project was co-financed through a grant by Kozloduy International Decommissioning fund (KIDSF) administrated by the EBRD and through Bulgarian national funding -Nuclear Facilities Decommissioning Fund and Radioactive Waste Fund. The KIDSF is funded by the European Union as well by the contributors to the KIDSF - Austria, Belgium, France, Greece, Ireland, The Netherlands, Spain, United Kingdom and Switzerland. (author)

12 MANAGEMENT OF RADIOACTIVE AND NON-RADIOACTIVE W↗

Methods for promoting myelination and for treating demyelinating diseases

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.

Lairson, Luke↗

Inhibition Kinetics And Emodin Cocrystal Structure of a Type II Polyketide Ketoreductase

Type II polyketides are a class of natural products that include pharmaceutically important aromatic compounds such as the antibiotic tetracycline and antitumor compound doxorubicin. The type II polyketide synthase (PKS) is a complex consisting of 5-10 standalone domains homologous to fatty acid synthase (FAS). Polyketide ketoreductase (KR) provides regio- and stereochemical diversity during the reduction. How the type II polyketide KR specifically reduces only the C9 carbonyl group is not well understood. The cocrystal structures of actinorhodin polyketide ketoreductase (actKR) bound with NADPH or NADP{sup +} and the inhibitor emodin were solved with the wild type and P94L mutant of actKR, revealing the first observation of a bent p-quinone in an enzyme active site. Molecular dynamics simulation help explain the origin of the bent geometry. Extensive screening for in vitro substrates shows that unlike FAS KR, the actKR prefers bicyclic substrates. Inhibition kinetics indicate that actKR follows an ordered Bi Bi mechanism. Together with docking simulations that identified a potential phosphopantetheine binding groove, the structural and functional studies reveal that the C9 specificity is a result of active site geometry and substrate ring constraints. The results lay the foundation for the design of novel aromatic polyketide natural products with different reduction patterns.

60 APPLIED LIFE SCIENCES↗

Crystal Structure And Functional Analysis of Tetracenomycin Aro/Cyc: Implications for Cyclization Specificity of Aromatic Polyketides

Polyketides are a class of natural products with highly diverse chemical structures and pharmaceutical activities. Polyketide cyclization, promoted by the aromatase/cyclase (ARO/CYC), helps diversify aromatic polyketides. How the ARO/CYC promotes highly specific cyclization is not well understood because of the lack of a first-ring ARO/CYC structure. The 1.9 {angstrom} crystal structure of Tcm ARO/CYC reveals that the enzyme belongs to the Bet v1-like superfamily (or STAR domain family) with a helix-grip fold, and contains a highly conserved interior pocket. Docking, mutagenesis, and an in vivo assay show that the size, shape, and composition of the pocket are important to orient and specifically fold the polyketide chain for C9-C14 first-ring and C7-C16 second-ring cyclizations. Two pocket residues, R69 and Y35, were found to be essential for promoting first- and second-ring cyclization specificity. Different pocket residue mutations affected the polyketide product distribution. A mechanism is proposed based on the structure-mutation-docking results. These results strongly suggest that the regiospecific cyclizations of the first two rings and subsequent aromatizations take place in the interior pocket. The chemical insights gleaned from this work pave the foundation toward defining the molecular rules for the ARO/CYC cyclization specificity, whose rational control will be important for future endeavors in the engineered biosynthesis of novel anticancer and antibiotic aromatic polyketides.

36 MATERIALS SCIENCE↗